GlassScriptPhysician profile
Lauren Clark
NPI 1043776891
$5,439.80
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,462 · 2022: $2,411 · 2023: $1,497 · 2024: $69.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $420.76 | 2021-2023 | Tivdak, Tukysa, Padcev |
| Amgen INC. | $416.00 | 2021-2023 | Lumakras, Kyprolis, Blincyto |
| Merck Sharp & Dohme LLC | $402.83 | 2021-2023 | Keytruda, Lynparza |
| Incyte Corporation | $339.92 | 2021-2023 | Jakafi |
| Novartis Pharmaceuticals Corporation | $337.02 | 2021-2023 | |
| Janssen Biotech, INC. | $286.28 | 2022-2024 | Erleada, Darzalex, Imbruvica |
| Astrazeneca Pharmaceuticals LP | $264.29 | 2021-2023 | Lynparza, Imfinzi, Calquence |
| Takeda Pharmaceuticals U.S.A., INC. | $241.11 | 2021-2024 | Iclusig, Gattex |
| E.R. Squibb & Sons, L.L.C. | $236.20 | 2021-2023 | Opdivo, Pomalyst |
| Eisai INC. | $187.97 | 2021-2022 | |
| Daiichi Sankyo INC. | $173.79 | 2021-2023 | Injectafer |
| Genzyme Corporation | $158.40 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $151.96 | 2021-2023 | Libtayo |
| Coherus Oncology, INC. | $143.76 | 2021-2022 | |
| Glaxosmithkline, LLC. | $141.81 | 2021-2023 | Jemperli, Zejula |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.